Godavari Biorefineries Q2 FY27 consolidated loss narrows as revenue rises to Rs 549.20 cr
For Q2 FY27, consolidated total income rose to Rs 549.80 cr while loss after tax narrowed to Rs (15.20) cr versus Rs (41.60) cr a year earlier.
Key takeaways
- Revenue from operations rose to Rs 549.20 cr in Q2 FY27 from Rs 430.80 cr in Q2 FY26.
- Total income increased to Rs 549.80 cr in Q2 FY27 versus Rs 434.30 cr a year earlier.
- EBITDA improved to Rs 10.90 cr in Q2 FY27 from Rs (4.40) cr in Q2 FY26.
- Profit/(Loss) after tax narrowed to Rs (15.20) cr from Rs (41.60) cr year-on-year.
- Finance costs increased to Rs 15.40 cr in Q2 FY27 compared with Rs 12.30 cr in Q2 FY26.
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 549.20 cr | Rs 430.80 cr | +27.5% |
| PAT | Rs (15.20) cr | Rs (41.60) cr | +63.4% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was -2.77% of revenue, up 688 bps from -9.66%.
• Basis & period: Consolidated statement of financial results, quarter ended 30 September 2026 (Q2 FY27) vs quarter ended 30 September 2025 (Q2 FY26), as per the consolidated P&L statement.
• Revenue from operations: Rs 549.20 cr in Q2 FY27, up from Rs 430.80 cr in Q2 FY26.
• Total income: Rs 549.80 cr in Q2 FY27, compared with Rs 434.30 cr in Q2 FY26.
• Cost of materials consumed: Rs 220.40 cr in Q2 FY27 vs Rs 146.20 cr in Q2 FY26.
• Purchase of finished goods: Rs 10.60 cr in Q2 FY27 vs Rs 9.50 cr in Q2 FY26.
• Changes in inventories of finished goods and WIP: Rs 198.70 cr in Q2 FY27 vs Rs 187.20 cr in Q2 FY26.
• Employee benefits expense: Rs 36.60 cr in Q2 FY27 vs Rs 31.50 cr in Q2 FY26.
• Other expenses: Rs 72.50 cr in Q2 FY27 vs Rs 64.20 cr in Q2 FY26.
• EBITDA*: Rs 10.90 cr in Q2 FY27 vs Rs (4.40) cr in Q2 FY26.
• Depreciation and amortisation expense: Rs 15.20 cr in Q2 FY27 vs Rs 13.50 cr in Q2 FY26.
• EBIT: Rs (4.40) cr in Q2 FY27 vs Rs (17.90) cr in Q2 FY26.
• Finance costs: Rs 15.40 cr in Q2 FY27 vs Rs 12.30 cr in Q2 FY26.
• Profit before exceptional expense: Rs (19.70) cr in Q2 FY27 vs Rs (30.20) cr in Q2 FY26.
• Exceptional expenses: Rs 0.00 cr in Q2 FY27 vs Rs 26.70 cr in Q2 FY26.
• Profit/(Loss) before tax for the period: Rs (19.70) cr in Q2 FY27 vs Rs (56.90) cr in Q2 FY26.
• Tax expense: Rs (4.50) cr in Q2 FY27 vs Rs (15.30) cr in Q2 FY26.
• Profit/(Loss) after tax: Rs (15.20) cr in Q2 FY27 vs Rs (41.60) cr in Q2 FY26.
In the consolidated P&L statement for Q2 FY27, Godavari Biorefineries reported higher revenue from operations of Rs 549.20 cr compared with Rs 430.80 cr in Q2 FY26. Total income rose to Rs 549.80 cr from Rs 434.30 cr over the same period. Cost of materials consumed increased to Rs 220.40 cr from Rs 146.20 cr, while purchase of finished goods moved to Rs 10.60 cr from Rs 9.50 cr. Changes in inventories of finished goods and WIP were Rs 198.70 cr versus Rs 187.20 cr a year earlier.
Employee benefits expense rose to Rs 36.60 cr from Rs 31.50 cr, and other expenses increased to Rs 72.50 cr from Rs 64.20 cr. EBITDA turned positive at Rs 10.90 cr in Q2 FY27 compared with Rs (4.40) cr in Q2 FY26. Depreciation and amortisation expense increased to Rs 15.20 cr from Rs 13.50 cr, and EBIT improved to Rs (4.40) cr from Rs (17.90) cr.
Finance costs rose to Rs 15.40 cr from Rs 12.30 cr. Profit before exceptional expense stood at Rs (19.70) cr in Q2 FY27 versus Rs (30.20) cr in Q2 FY26. There were exceptional expenses of Rs 0.00 cr in Q2 FY27 compared with Rs 26.70 cr in Q2 FY26. Profit/(Loss) before tax for the period improved to Rs (19.70) cr from Rs (56.90) cr, and tax expense was Rs (4.50) cr versus Rs (15.30) cr. As a result, profit/(loss) after tax narrowed to Rs (15.20) cr in Q2 FY27 from Rs (41.60) cr in the corresponding quarter of the previous year.
Track Godavari Biorefineries Ltd
Cruxal reads every Godavari Biorefineries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
